NOX1 and type 2 diabetes mellitus: However, a clinical trial outcome in patients with type 2 diabetes and kidney disease by Genkyotex using a dual NOX1/4 inhibitor, GKT137831, was negative as the inhibitor was unable to reduce albuminuria, which was the primary endpoint [33].